We observed that the peri-surgical treatment with p70S6K inhibitors, targeting residual breast cancer cells when conceivably they were more vulnerable, was sufficient to achieve a better locoregional disease control [9]. This evidence concerns the gene RPS6KB1 and breast carcinoma.